Kymera Therapeutics (KYMR)

• Market cap: $1.99B
• 1 day: 6.60%
• 5 days: 21.78%
• 1 month: -8.90%
• 3 months: -30.59%
• 6 months: -37.04%
• Year to date: -24.92%
• 1 year: -14.03%
• 5 years: -7.70%
• 10 years: -7.70%
• Sector: Healthcare
• Industry: Biotechnology

About: Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Employees: 188

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

326% more call options, than puts

Call options by funds: $3M | Put options by funds: $704K

29% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]

21% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 28

2.59% more ownership

Funds ownership: 108.16% [Q3] → 110.75% (+2.59%) [Q4]

2% more funds holding

Funds holding: 175 [Q3] → 179 (+4) [Q4]

5% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 58

12% less capital invested

Capital invested by funds: $3.26B [Q3] → $2.89B (-$379M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $52 69% upside
• Avg. target: $56 82% upside
• High target: $60 95% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Geoff Meacham 27% 1-year accuracy 9 / 33 met price target	69% upside $52	Buy Initiated	13 Mar 2025
HC Wainwright & Co. Andrew Fein 26% 1-year accuracy 93 / 355 met price target	95% upside $60	Buy Maintained	28 Feb 2025